Form D · Other Technology
NeuroLambda Therapeutics, Inc.
Cambridge, MA · CIK 0002029691
Offering snapshot reported Jul 17, 2024 · SEC filing
- Reported sold
- $3M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 21, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 17, 2024 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-519102
Source: Form D, filed Jul 17, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Xiaowei Jin | Director |
| Byungchan Kim | Director |
| Sayan Mondal | Director, Executive |
Issuer details
Industry: Other Technology (See others in industry)
Address:
1 Broadway, 14th Floor
Cambridge, MA, 02142
Cambridge, MA, 02142